Gene Therapy Zynteglo denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Zynteglo for Medical Necessity — and Why You Can Appeal

Blue Cross Blue Shield's medical-necessity denials for Zynteglo (betibeglogene spartacus) typically stem from a plan reviewer's conclusion that the clinical record does not sufficiently demonstrate that the patient meets all criteria in BCBS's coverage policy for gene therapy in transfusion-dependent beta-thalassemia. This is often a documentation gap rather than a clinical one — meaning the underlying need is real but the file submitted did not make it explicit.

## Why This Denial Is Appealable

Medical-necessity denials are among the most successfully overturned on appeal because they depend entirely on what documentation was in front of the reviewer. When a complete, organized record is submitted — including detailed treatment history, objective disease-severity data, and a thorough prescriber letter — reviewers and Independent Review Organizations frequently reverse the denial.

## Federal Appeal Framework

• Internal appeal (Level 1): Required first under ACA §2719 and ERISA §503. Deadlines vary by plan type — check your denial letter. Typical windows are 180 days from denial.
• External review: After an adverse internal determination, you may request IRO review. The external-review request window is typically 4 months from the final adverse decision. Verify the exact date on your denial notice.
• Expedited option: Request expedited review (72-hour decision) if delay would seriously jeopardize health or the ability to regain maximum function.

## Documentation to Gather

1. Diagnosis confirmation: Genetic testing report and clinical records confirming transfusion-dependent beta-thalassemia, including genotype. 2. Transfusion dependency history: Comprehensive transfusion records with dates, units transfused, and frequency over time, demonstrating the ongoing burden. 3. Prior treatment history with outcomes: Documentation of all prior therapies — chelation, supportive care, any prior pharmacologic approaches — with dates, doses, duration, and reasons for inadequacy or discontinuation. 4. Clinical severity documentation: Chart notes detailing iron overload, organ involvement, quality-of-life burden, and any complications of chronic transfusion therapy. 5. Prescriber medical-necessity letter: A detailed letter from the treating hematologist explaining why Zynteglo is medically necessary for this specific patient, referencing the FDA-approved prescribing label criteria and the applicable professional society guidelines.

## Criteria-Mapping Structure

Request BCBS's current published medical policy for Zynteglo or gene therapy for beta-thalassemia. Extract each listed coverage criterion. Then build a one-to-one map:

| BCBS Coverage Criterion | Supporting Chart Evidence | |---|---| | Confirmed diagnosis of transfusion-dependent beta-thalassemia | [Genetic report date, confirming genotype] | | Documentation of transfusion burden | [Transfusion log showing frequency and volume] | | Failure or inadequacy of prior standard therapy | [Treatment history with dates and outcomes] | | Treating physician attestation of medical necessity | [Prescriber letter referencing FDA label and guidelines] |

For the exact eligibility thresholds and criteria BCBS requires, consult the insurer's published medical/coverage policy directly — do not rely on summaries. Confirm with your prescriber that each threshold is met and documented in the chart before submitting.